These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 12861106)

  • 41. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
    Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
    J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Side effects, unwanted drug interactions and the problem of cardiotoxicity].
    Woroń J; Trabka-Janik E; Kostka-Trabka E
    Przegl Lek; 2003; 60(4):196-8. PubMed ID: 14569882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
    Wolbrette D
    Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug.
    Husain Z; Hussain K; Nair R; Steinman R
    Cardiol J; 2010; 17(5):509-11. PubMed ID: 20865683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arrhythmias associated with fluoroquinolone therapy.
    Falagas ME; Rafailidis PI; Rosmarakis ES
    Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Torsade de pointes and low-dose oral haloperidol.
    Jackson T; Ditmanson L; Phibbs B
    Arch Intern Med; 1997 Sep; 157(17):2013-5. PubMed ID: 9308514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protease inhibitor-associated QT interval prolongation.
    Hunt K; Hughes CA; Hills-Nieminen C
    Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical characteristics of 52 patients with torsade de points associated with acquired QT prolongation].
    Song L; Yang YM; Zhu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Apr; 39(4):293-6. PubMed ID: 21624301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. QT interval prolongation and torsade de pointes.
    Patanè S; Marte F; Di Bella G
    Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
    Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
    J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methadone-induced torsade de pointes in a patient with normal baseline QT interval.
    Almehmi A; Malas AM; Yousufuddin M; Rosencrance JG
    W V Med J; 2004; 100(4):147-8. PubMed ID: 15471174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long QT-syndrome as a drug-induced side effect].
    Pohjola-Sintonen S
    Duodecim; 1998; 114(19):1891, 1893, 1895. PubMed ID: 11717743
    [No Abstract]   [Full Text] [Related]  

  • 54. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.
    Yap YG; Camm J
    BMJ; 2000 Apr; 320(7243):1158-9. PubMed ID: 10784527
    [No Abstract]   [Full Text] [Related]  

  • 55. Drug-induced long QT syndrome and Torsade de Pointes.
    Chism S; Smith E
    J Ark Med Soc; 2004 Jul; 101(1):24-6. PubMed ID: 15270138
    [No Abstract]   [Full Text] [Related]  

  • 56. [Drug-induced long QT syndrome and torsade de pointes arrhythmias].
    Dhein S
    Dtsch Med Wochenschr; 2000 Jun; 125(22):703-8. PubMed ID: 10874898
    [No Abstract]   [Full Text] [Related]  

  • 57. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
    Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
    Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity.
    Nogales Asensio JM; Moreno Sánchez N; Doncel Vecino LJ; Villar Mariscal C; López-Mínguez JR; Merchán Herrera A
    Int J Cardiol; 2007 Jan; 114(2):E65-7. PubMed ID: 17056139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Amiodarone-induced torsade de pointes--five case reports].
    Kukla P; Słowiak-Lewińska T
    Kardiol Pol; 2004 Apr; 60(4):365-70; discussion 371. PubMed ID: 15226788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
    Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ
    Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.